Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) shares reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $5.83 and last traded at $5.8350, with a volume of 1228 shares trading hands. The stock had previously closed at $5.92.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on CLPBY. Kepler Capital Markets raised shares of Coloplast A/S to a “strong-buy” rating in a report on Wednesday, May 20th. The Goldman Sachs Group downgraded Coloplast A/S from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Coloplast A/S presently has an average rating of “Hold”.
View Our Latest Analysis on CLPBY
Coloplast A/S Stock Down 1.5%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. Coloplast A/S had a return on equity of 31.96% and a net margin of 7.46%.The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.11 billion. Sell-side analysts anticipate that Coloplast A/S Sponsored ADR will post 0.4 EPS for the current fiscal year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Further Reading
- Five stocks we like better than Coloplast A/S
- Microsoft’s Xbox Problem Is Bigger Than a Console War
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
- Bread’s Comeback Is Real—But Is the Easy Money Gone?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
